BCM-599

• Description:

  BCM-599 is a HBV (hepatitis B virus) capsid assembly inhibitor with the activity of inhibiting HBV capsid assembly. BCM-599 showed an IC50 value of 0.88μM and a CC50 value of 144μM in HepG2.2.15 cells. When used in combination with lamivudine, BCM-599 showed a synergistic inhibitory effect on viral concentration. BCM-599 can be used as an effective combined inhibition option for HBV infection[1].

• UNSPSC:

  12352005

• Target:

  Endogenous Metabolite

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/bcm-599.html

• Smiles:

  FC1=CC=C (C=C1) C (NCC (NC2=C (N=C (C=C2) Cl) Cl) =O) =O

• Molecular Formula:

  C14H10Cl2FN3O2

• Molecular Weight:

  342.15

• References & Citations:

  [1]2-amino-N- (2,6-dichloropyridin-3-yl) acetamide derivatives as a novel class of HBV capsid assembly inhibitor

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1820763-99-2